
  
    
      
        Background_NNP
        Dystrophinopathies_NNP are_VBP X-_NNP linked_VBN recessive_JJ diseases_NNS
        caused_VBN by_IN primary_JJ dystrophin_NN deficiency_NN ,_, and_CC include_VBP :_:
        Duchenne_NNP Muscular_NNP Dystrophy_NNP (_( DMD_NNP )_) ,_, Becker_NNP Muscular_NNP
        Dystrophy_NNP (_( BMD_NNP )_) ,_, manifesting_VBG DMD_NNP /_NN BMD_NNP carrier_NN females_NNS ,_,
        X-_NNP linked_VBD dilated_JJ cardiomyopathy_NN ,_, isolated_VBN quadriceps_NNS
        myopathy_NN ,_, muscle_NN cramps_NNS with_IN myoglobinuria_NN and_CC asymptomatic_JJ
        elevation_NN of_IN muscle_NN enzymes_NNS [_NN 1_CD ]_NN ._.
        The_DT DMD_NNP gene_NN spans_NNS 2_CD ._. 4_CD million_CD base_NN pairs_NNS of_IN genomic_JJ DNA_NNP
        on_IN the_DT X_NNP chromosome_NN and_CC its_PRP$ 14_CD kb_NN transcript_NN encodes_NNS a_DT
        full-length_JJ protein_NN (_( dystrophin_NN )_) of_IN 427_CD kiloDaltons_NNS ._.
        Dystrophin_NNP is_VBZ a_DT sarcolemmal_NN protein_NN that_IN through_IN its_PRP$
        interaction_NN with_IN many_JJ other_JJ proteins_NNS participates_VBZ in_IN the_DT
        linkage_NN of_IN the_DT extracellular_NN matrix_NN to_TO the_DT cytoplasmic_JJ
        cytoskeleton_NN [_NN 2_CD 3_CD 4_CD ]_NN ._. Mutations_NNP in_IN this_DT gene_NN result_NN in_IN
        DMD_NNP ,_, BMD_NNP or_CC other_JJ dystrophinopathy_NN ._. A_DT major_JJ consequence_NN of_IN
        the_DT dystrophin_NN gene_NN 's_POS large_JJ genomic_JJ size_NN is_VBZ a_DT high_JJ rate_NN of_IN
        mutation_NN ;_: close_RB to_TO 30_CD %_NN of_IN cases_NNS prove_VBP to_TO be_VB spontaneous_JJ
        mutations_NNS [_NN 5_CD ]_NN ._. Approximately_RB 60_CD %_NN of_IN mutations_NNS causing_VBG
        DMD_NNP are_VBP deletions_NNS of_IN large_JJ segments_NNS of_IN the_DT gene_NN usually_RB
        including_VBG one_CD or_CC more_JJR exons_NNS [_NN 6_CD 7_CD 8_CD ]_NN ._. Approximately_RB 5_CD %_NN of_IN
        mutations_NNS are_VBP duplications_NNS of_IN large_JJ segments_NNS of_IN the_DT gene_NN [_NN
        8_CD ]_NN ._. Large_JJ deletions_NNS and_CC duplications_NNS are_VBP detected_VBN using_VBG
        multiplexed_JJ PCR_NNP primers_NNS to_TO amplify_VB a_DT subset_NN of_IN
        (_( approximately_RB 20_CD of_IN the_DT 79_CD )_) exons_NNS that_WDT are_VBP empirically_RB
        estimated_VBN to_TO constitute_VB 98_CD %_NN of_IN large_JJ deletions_NNS and_CC
        duplications_NNS ._. Thus_RB ,_, most_JJS but_CC not_RB all_DT large_JJ deletions_NNS and_CC
        duplications_NNS are_VBP detected_VBN by_IN this_DT test_NN [_NN 9_CD 10_CD ]_NN ._. The_DT other_JJ
        35_CD %_NN of_IN mutations_NNS are_VBP presumed_VBN to_TO be_VB point_NN mutations_NNS such_JJ
        as_IN ,_, substitutions_NNS ,_, deletions_NNS or_CC insertions_NNS of_IN one_CD or_CC
        several_JJ nucleotides_NNS leading_VBG to_TO premature_JJ termination_NN codons_NNS
        (_( nonsense_NN or_CC frame-shift_JJ mutations_NNS )_) ,_, amino_JJ acid_NN
        substitutions_NNS (_( missense_NN and_CC neutral_JJ mutations_NNS )_) and_CC
        alterations_NNS in_IN splice_NN sites_NNS ._. These_DT mutations_NNS have_VBP remained_VBN
        undetected_JJ in_IN most_JJS patients_NNS ,_, both_DT male_JJ and_CC female_JJ ,_, because_IN
        available_JJ techniques_NNS are_VBP relatively_RB expensive_JJ and_CC laborious_JJ
        given_VBN the_DT size_NN of_IN the_DT dystrophin_NN gene_NN ._. Existing_JJ procedures_NNS
        for_IN detection_NN of_IN point_NN mutations_NNS include_VBP SSCP_NNP (_( single_JJ
        strand_NN conformational_NN polymorphism_NN )_) [_NN 11_CD 12_CD ]_NN ,_, a_DT variation_NN
        of_IN SSCP_NNP called_VBD DOVAM_NNP (_( Detection_NNP of_IN Virtually_RB All_DT Mutations_NNP )_)
        [_NN 19_CD ]_NN ,_, Enhanced_NNP SSCP_NNP [_NN 28_CD ]_NN ,_, HA_NNP (_( Heteroduplex_NNP Analysis_NNP )_)
        [_NN 13_CD 14_CD ]_NN ,_, PTT_NNP (_( Protein_NNP Truncation_NNP Test_NNP )_) [_NN 15_CD ]_NN ,_, DGGE_NNP
        (_( Denaturing_NNP Gradient_NNP Gel_NNP Electrophoresis_NNP )_) [_NN 16_CD 17_CD 18_CD ]_NN ,_,
        chemical_NN cleavage_NN of_IN mismatch_NN [_NN 20_CD ]_NN ,_, and_CC RNase_NNP cleavage_NN [_NN
        21_CD ]_NN ._. Each_DT of_IN these_DT procedures_NNS has_VBZ its_PRP$ advantages_NNS and_CC
        limitations_NNS but_CC the_DT size_NN of_IN the_DT gene_NN and_CC the_DT cost_NN of_IN the_DT
        procedures_NNS have_VBP not_RB made_VBN them_PRP routine_JJ in_IN most_JJS
        laboratories_NNS ._.
        The_DT purpose_NN of_IN this_DT project_NN was_VBD to_TO develop_VB an_DT effective_JJ
        and_CC convenient_JJ process_NN to_TO detect_VB both_DT large_JJ and_CC small_JJ
        alterations_NNS in_IN the_DT DMD_NNP gene_NN with_IN only_RB a_DT moderate_JJ increase_NN
        in_IN cost_NN ._. In_IN an_DT effort_NN to_TO address_VB these_DT issues_NNS ,_, we_PRP developed_VBD
        a_DT new_JJ primer_NN set_VBN to_TO be_VB used_VBN in_IN conjunction_NN with_IN denaturing_VBG
        high-performance_JJ liquid_JJ chromatography_NN (_( DHPLC_NNP )_) and_CC
        dye-terminator_JJ sequencing_VBG ._. DHPLC_NNP has_VBZ been_VBN developed_VBN to_TO
        screen_VB for_IN DNA_NNP variations_NNS by_IN separating_VBG heteroduplex_NN and_CC
        homoduplex_NN DNA_NNP fragments_NNS by_IN ion-pair_JJ reverse-phase_JJ liquid_JJ
        chromatography_NN [_NN 22_CD ]_NN ._. We_PRP used_VBD this_DT technique_NN to_TO study_VB
        eight_CD male_JJ patients_NNS and_CC one_CD female_JJ carrier_NN relative_NN of_IN one_CD
        of_IN the_DT eight_CD males_NNS ._. Since_IN this_DT technique_NN separates_NNS
        heteroduplexes_NNS and_CC homoduplexes_NNS ,_, it_PRP can_MD also_RB be_VB used_VBN to_TO
        analyze_VB manifesting_VBG and_CC carrier_NN females_NNS with_IN point_NN
        mutations_NNS ._.
      
      
        Results_NNS
        We_PRP started_VBD the_DT project_NN with_IN the_DT intention_NN of_IN designing_VBG
        primers_NNS to_TO amplify_VB and_CC sequence_NN all_DT of_IN the_DT exons_NNS of_IN the_DT
        dystrophin_NN gene_NN as_RB well_RB as_IN the_DT 3_CD '_POS -_: UTR_NNP and_CC 5_CD '_POS -_: UTR_NNP ._. In_IN order_NN
        to_TO ensure_VB detection_NN of_IN splice_NN site_NN as_RB well_RB as_IN exon_NN sequence_NN
        alterations_NNS ,_, genomic_JJ sequence_NN surrounding_VBG each_DT of_IN the_DT
        sequence-known_JJ fragments_NNS of_IN dystrophin_NN was_VBD mined_JJ from_IN the_DT
        NIH_NNP GenBank_NNP database_NN ._. Primers_NNP were_VBD designed_VBN (_( see_VB methods_NNS )_)
        that_WDT allowed_VBD for_IN amplification_NN of_IN a_DT product_NN with_IN 30_CD -_: 100_CD
        bases_NNS on_IN either_DT side_NN of_IN each_DT exon_NN ._. To_TO look_VB for_IN point_NN
        mutations_NNS ,_, eight_CD patients_NNS were_VBD chosen_VBN as_IN test_NN cases_NNS based_VBN
        on_IN the_DT absence_NN of_IN dystrophin_NN ,_, clinical_JJ symptoms_NNS consistent_JJ
        with_IN DMD_NNP and_CC no_DT large_JJ deletion_NN or_CC duplication_NN detected_VBN by_IN
        the_DT multiplexed_JJ PCR_NNP test_NN ._. In_IN addition_NN ,_, one_CD sister_NN thought_VBD
        to_TO be_VB a_DT carrier_NN female_NN was_VBD also_RB tested_VBN as_IN described_VBN in_IN the_DT
        methods_NNS and_CC summarized_VBD in_IN Table_NNP 1_CD ._.
        Initially_RB the_DT primers_NNS were_VBD used_VBN to_TO prepare_VB amplicons_NNS of_IN
        dystrophin_NN exons_NNS for_IN direct_JJ sequencing_VBG ._. Likely_JJ
        disease-causative_JJ mutations_NNS were_VBD found_VBN in_IN four_CD of_IN the_DT
        patients_NNS and_CC confirmed_VBD in_IN the_DT female_JJ relative_NN of_IN patient_NN 01_CD
        by_IN direct_JJ sequencing_VBG of_IN exons_NNS 2_CD through_IN 55_CD ,_, and_CC the_DT three_CD
        5_CD '_POS -_: UTR_NNP fragments_NNS ,_, the_DT last_NN of_IN which_WDT includes_VBZ the_DT dp_NN 427_CD m_NN
        promoter_NN and_CC exon_NN 1_CD ._. These_DT were_VBD sequenced_JJ prior_RB to_TO our_PRP$
        obtaining_VBG the_DT DHPLC_NNP system_NN for_IN screening_NN ._. When_WRB a_DT likely_JJ
        disease-causative_JJ mutation_NN was_VBD found_VBN in_IN each_DT of_IN these_DT
        patients_NNS ,_, no_DT further_JJ fragments_NNS were_VBD sequenced_JJ for_IN that_DT
        patient_NN ._. Patient_NNP 01_CD and_CC his_PRP$ carrier_NN sister_NN were_VBD shown_VBN to_TO
        have_VB a_DT C-_NNP >_NN T_NN substitution_NN in_IN exon_NN 39_CD bp_NN 5762_CD ,_, predicting_VBG a_DT
        nonsense_NN mutation_NN Gln-_NNP >_NN Stop_NNP ,_, leading_VBG to_TO a_DT likely_JJ
        disease-causative_JJ truncation_NN of_IN the_DT protein_NN (_( Table_NNP 2_CD and_CC
        Figure_NN 1_LS )_) ._.
        Patient_NNP 02_CD has_VBZ an_DT 11_CD bp_NN deletion_NN in_IN exon_NN 41_CD and_CC patient_NN
        03_CD is_VBZ missing_VBG exon_NN 21_CD which_WDT was_VBD not_RB recognized_VBN until_IN the_DT
        end_NN of_IN the_DT project_NN and_CC had_VBD not_RB been_VBN detected_VBN by_IN the_DT
        multiplexed_JJ PCR_NNP test_NN because_IN exon_NN 21_CD is_VBZ not_RB one_CD of_IN the_DT
        included_VBN exons_NNS in_IN that_DT test_NN ._. These_DT two_CD mutations_NNS both_DT
        create_VB out_IN of_IN frame_NN transcripts_NNS leading_VBG to_TO eventual_JJ stop_NN
        codons_NNS and_CC premature_JJ truncation_NN of_IN the_DT protein_NN ._. Patient_NNP 07_CD
        has_VBZ a_DT C-_NNP >_NN T_NN substitution_NN in_IN exon_NN 23_CD at_IN bp_NN 3359_CD predicting_VBG
        a_DT nonsense_NN mutation_NN Arg-_NNP >_NN Stop_NNP ,_, leading_VBG to_TO a_DT likely_JJ
        disease-causative_JJ truncation_NN of_IN the_DT protein_NN ._. Patient_NNP 04_CD has_VBZ
        a_DT G-_NNP >_NN T_NN substitution_NN at_IN base_NN 738_CD +_NN 1_CD of_IN the_DT intron_NN 6_CD splice_NN
        site_NN ._. This_DT donor_NN splice_NN site_NN is_VBZ normally_RB a_DT G_NNP but_CC in_IN 1805_CD
        sites_NNS examined_VBD in_IN the_DT human_JJ genome_NN ,_, only_RB 8_CD times_NNS is_VBZ it_PRP a_DT T_NN
        [_NN 23_CD ]_NN ._. The_DT predicted_VBN aberrant_NN splicing_VBG of_IN exon_NN 7_CD makes_VBZ
        this_DT a_DT likely_JJ causative_JJ mutation_NN in_IN this_DT patient_NN ._.
        The_DT DHPLC_NNP system_NN was_VBD obtained_VBN halfway_RB into_IN the_DT study_NN and_CC
        four_CD patients_NNS '_POS exons_NNS 56_CD through_IN 78_CD and_CC the_DT 3_CD '_POS -_: UTR_NNP including_VBG
        exon_NN 79_CD were_VBD analyzed_VBN on_IN the_DT DHPLC_NNP system_NN prior_RB to_TO sequence_NN
        analysis_NN ._. In_IN the_DT DHPLC_NNP system_NN ,_, fragments_NNS are_VBP screened_VBD for_IN
        variation_NN in_IN retention_NN time_NN or_CC chromatogram_NN shape_NN from_IN that_DT
        of_IN an_DT unaffected_JJ control_NN amplicon_NN ._. Fragments_NNP exhibiting_VBG
        variation_NN are_VBP then_RB sequenced_JJ for_IN confirmation_NN and_CC analysis_NN ._.
        Two_CD variations_NNS were_VBD detected_VBN by_IN DHPLC_NNP ,_, both_DT in_IN exon_NN 59_CD ,_, for_IN
        patients_NNS 05_CD and_CC 06_CD (_( Figure_NN 2_CD a_DT )_) (_( only_RB patient_NN 06_CD shown_VBN )_) ._.
        These_DT two_CD fragments_NNS were_VBD sequenced_JJ and_CC a_DT
        non-disease-causative_JJ Gln-_NNP >_NN Arg_NNP missense_NN mutation_NN at_IN bp_NN
        9018_CD was_VBD found_VBN in_IN both_DT patients_NNS ._. As_IN we_PRP found_VBD no_DT likely_JJ
        disease-causative_JJ mutations_NNS in_IN our_PRP$ first_JJ pass_NN DHPLC_NNP
        conditions_NNS ,_, we_PRP sequenced_JJ all_DT four_CD patients_NNS exons_NNS 56_CD -_: 78_CD and_CC
        the_DT 7_CD fragments_NNS of_IN the_DT 3_CD '_POS -_: UTR_NNP (_( the_DT first_NN of_IN which_WDT contains_VBZ
        exon_NN 79_CD )_) ._. Only_RB two_CD of_IN the_DT 116_CD fragments_NNS (_( 4_CD patients_NNS x_SYM 29_CD
        fragments_NNS each_DT )_) sequenced_JJ showed_VBD alterations_NNS which_WDT were_VBD not_RB
        detected_VBN by_IN the_DT first_JJ pass_NN temperatures_NNS chosen_VBN for_IN DHPLC_NNP
        analysis_NN ._. The_DT first_JJ is_VBZ a_DT polymorphism_NN ,_, 9857_CD +_NN 15_CD C-_NNP >_NN T_NN in_IN
        intron_NN 66_CD ,_, in_IN patient_NN 06_CD ._. The_DT second_NN is_VBZ a_DT probable_JJ novel_NN
        disease-causative_JJ mutation_NN ,_, 10015_CD +_NN 5_CD G-_NNP >_NN A_DT in_IN intron_NN 67_CD ,_,
        within_IN the_DT splice_NN site_NN consensus_NN sequence_NN in_IN patient_NN 08_CD ._.
        Based_VBN on_IN 1788_CD donor_NN sites_NNS from_IN the_DT human_JJ genome_NN ,_, 128_CD
        (_( 7_CD ._. 16_CD %_NN )_) were_VBD adenosine_NN while_IN 1468_CD (_( 82_CD ._. 1_LS %_NN )_) were_VBD guanosine_NN at_IN
        this_DT position_NN in_IN the_DT splice_NN sequence_NN making_VBG it_PRP likely_JJ that_DT
        exon_NN 68_CD will_MD be_VB aberrantly_RB spliced_JJ [_NN 23_CD ]_NN ._. When_WRB these_DT two_CD
        fragments_NNS were_VBD run_VBN on_IN the_DT DHPLC_NNP system_NN at_IN the_DT lower_JJR second_JJ
        pass_NN temperatures_NNS indicated_VBD in_IN Additional_JJ file_NN A_DT :_: Primer_NNP
        sequences_NNS and_CC DHPLC_NNP temperatures_NNS Excel_NNP spreadsheet_NN ,_, the_DT
        alterations_NNS were_VBD detected_VBN (_( Figure_NN 2_CD cand_NN 2_CD b_SYM )_) ._. In_IN addition_NN ,_,
        the_DT four_CD previously_RB identified_VBN mutations_NNS were_VBD confirmed_VBN on_IN
        the_DT DHPLC_NNP system_NN ,_, as_IN was_VBD the_DT carrier_NN status_NN of_IN patient_NN 01_CD S_NNP
        (_( Figure_NN 3_LS )_) ._.
        In_IN total_JJ ,_, likely_JJ disease-causative_JJ mutations_NNS were_VBD found_VBN
        in_IN six_CD of_IN the_DT eight_CD male_JJ patients_NNS and_CC confirmed_VBD in_IN the_DT
        carrier_NN sister_NN (_( patient_NN 01_CD s_VBZ )_) of_IN one_CD of_IN the_DT six_CD patients_NNS
        (_( patient_NN 01_CD )_) ._. In_IN addition_NN ,_, one_CD silent_JJ and_CC five_CD neutral_JJ
        polymorphisms_NNS ,_, and_CC six_CD intronic_JJ alterations_NNS that_WDT have_VBP
        previously_RB been_VBN shown_VBN to_TO be_VB present_JJ in_IN unaffected_JJ
        individuals_NNS were_VBD found_VBN ._. One_CD silent_JJ polymorphism_NN and_CC eight_CD
        previously_RB unreported_JJ intronic_JJ alterations_NNS were_VBD also_RB found_VBN ._.
        In_IN two_CD patients_NNS ,_, 05_CD and_CC 06_CD ,_, we_PRP did_VBD not_RB find_VB likely_JJ
        disease-causative_JJ mutations_NNS despite_IN sequencing_VBG all_DT 86_CD
        fragments_NNS ._.
      
      
        Discussion_NNP
        We_PRP used_VBD a_DT combination_NN of_IN direct_JJ sequencing_VBG and_CC DHPLC_NNP to_TO
        search_VB for_IN mutations_NNS in_IN 8_CD patients_NNS with_IN DMD_NNP and_CC a_DT carrier_NN
        sister_NN ._. Likely_JJ causative_JJ mutations_NNS were_VBD found_VBN in_IN 6_CD of_IN 8_CD
        males_NNS and_CC confirmed_VBD in_IN the_DT carrier_NN sister_NN of_IN one_CD ._. In_IN our_PRP$
        study_NN ,_, one_CD likely_JJ causative_JJ mutation_NN (_( patient_NN 03_CD del_FW exn_NN 21_CD )_)
        was_VBD found_VBN just_RB by_IN PCR_NNP analysis_NN and_CC 5_CD likely_JJ causative_JJ
        mutations_NNS were_VBD first_RB detected_VBN by_IN direct_JJ sequencing_VBG but_CC each_DT
        was_VBD subsequently_RB detected_VBN by_IN DHPLC_NNP ._. Our_PRP$ experience_NN
        indicates_VBZ that_IN the_DT multiple_JJ different_JJ conditions_NNS of_IN DHPLC_NNP
        would_MD have_VB detected_VBN all_DT of_IN these_DT likely_JJ causative_JJ mutations_NNS
        and_CC all_DT polymorphisms_NNS ._. Direct_NNP sequencing_VBG of_IN all_PDT the_DT
        fragments_NNS is_VBZ still_RB more_RBR costly_JJ than_IN DHPLC_NNP and_CC our_PRP$ results_NNS
        indicate_VBP that_IN initial_JJ analysis_NN using_VBG the_DT far_RB cheaper_JJR DHPLC_NNP
        should_MD precede_VB sequencing_VBG thus_RB reducing_VBG cost_NN of_IN the_DT
        analysis_NN ._. Causative_NNP mutations_NNS were_VBD not_RB found_VBN in_IN two_CD of_IN the_DT
        eight_CD patients_NNS ._. Due_JJ to_TO the_DT enormous_JJ size_NN of_IN the_DT dystrophin_NN
        gene_NN (_( 2_CD ._. 4_LS million_CD base_NN pairs_NNS )_) ,_, finding_VBG 100_CD %_NN of_IN mutations_NNS is_VBZ
        improbable_JJ using_VBG these_DT fragments_NNS because_IN we_PRP cannot_NN examine_VBP
        all_PDT the_DT sequences_NNS and_CC situations_NNS that_WDT might_MD affect_VB
        expression_NN ._. It_PRP is_VBZ possible_JJ ,_, but_CC unlikely_JJ ,_, that_IN one_CD of_IN the_DT
        currently_RB unknown_JJ alterations_NNS that_IN we_PRP found_VBD in_IN patients_NNS 05_CD
        and_CC 06_CD will_MD eventually_RB be_VB proven_VBN a_DT causative_JJ mutation_NN
        rather_RB than_IN a_DT polymorphism_NN ._.
        Two_CD of_IN the_DT patients_NNS in_IN which_WDT we_PRP found_VBD disease-causative_JJ
        mutations_NNS have_VBP affected_VBN brothers_NNS ,_, three_CD in_IN addition_NN to_TO
        patient_NN 01_CD ,_, have_VBP potential_JJ carrier_NN sisters_NNS ,_, and_CC all_DT six_CD
        have_VBP mothers_NNS who_WP could_MD also_RB be_VB carriers_NNS ._. We_PRP have_VBP shown_VBN
        that_IN ,_, 1_LS )_) using_VBG the_DT DHPLC_NNP system_NN ,_, it_PRP is_VBZ now_RB not_RB only_RB
        feasible_JJ but_CC actually_RB a_DT simple_JJ process_NN to_TO determine_VB if_IN any_DT
        of_IN these_DT relatives_NNS have_VBP the_DT same_JJ point_NN mutation_NN as_IN their_PRP$
        brother_NN /_NN son_NN and_CC ,_, 2_LS )_) that_DT carrier_NN testing_NN and_CC pre-natal_JJ
        diagnostic_JJ testing_NN is_VBZ now_RB available_JJ to_TO any_DT of_IN these_DT
        patients_NNS who_WP wish_VBP to_TO use_VB it_PRP ._.
        As_IN larger_JJR cohorts_NNS of_IN patients_NNS are_VBP tested_VBN ,_, a_DT more_RBR
        accurate_JJ estimate_NN of_IN the_DT percentage_NN of_IN undetectable_JJ
        causative_JJ mutations_NNS will_MD emerge_VB and_CC present_VB a_DT clear_JJ new_JJ
        challenge_NN ._. We_PRP estimate_VBP based_VBN on_IN our_PRP$ small_JJ sample_NN ,_, and_CC other_JJ
        unpublished_JJ data_NNS ,_, that_IN such_JJ cases_NNS will_MD comprise_VB a_DT small_JJ
        percentage_NN (_( less_JJR than_IN 8_CD percent_NN )_) of_IN total_JJ DMD_NNP cases_NNS ._.
        Possible_JJ explanations_NNS for_IN such_JJ cases_NNS include_VBP duplications_NNS
        which_WDT we_PRP may_MD have_VB missed_VBN ,_, mutations_NNS in_IN unknown_JJ enhancers_NNS or_CC
        translation_NN modifiers_NNS hidden_VBN in_IN exons_NNS or_CC introns_NNS ,_, mutations_NNS
        that_WDT create_VBP novel_NN splice_NN sites_NNS and_CC changes_NNS in_IN the_DT coding_VBG
        region_NN which_WDT might_MD be_VB pathogenic_JJ but_CC which_WDT ,_, due_JJ to_TO our_PRP$ lack_NN
        of_IN knowledge_NN ,_, are_VBP thought_VBN to_TO be_VB polymorphic_JJ ._. For_IN example_NN ,_,
        changes_VBZ to_TO an_DT amino_JJ acid_NN that_WDT is_VBZ essential_JJ for_IN some_DT
        protein_NN /_NN protein_NN interaction_NN (_( potentially_RB transportation_NN )_) ,_,
        or_CC is_VBZ modified_VBN /_NN processed_VBN on_IN the_DT protein_NN level_NN but_CC which_WDT we_PRP
        currently_RB assume_VBP is_VBZ just_RB a_DT polymorphic_JJ change_NN ._. Other_JJ
        possible_JJ mechanisms_NNS include_VBP mosaicism_NN ,_, in_IN which_WDT DNA_NNP
        extracted_VBD from_IN blood_NN lymphocytes_NNS has_VBZ different_JJ sequence_NN
        than_IN DNA_NNP extracted_VBD from_IN muscle_NN cells_NNS ,_, and_CC cryptic_JJ
        chromosomal_NN rearrangements_NNS ._. These_DT will_MD require_VB dedicated_VBN
        efforts_NNS to_TO resolve_VB either_CC individually_RB case_NN by_IN case_NN or_CC to_TO
        develop_VB new_JJ ,_, more_RBR comprehensive_JJ ,_, routine_JJ tests_NNS ,_, including_VBG
        RNA_NNP and_CC protein_NN analysis_NN ._. Fortunately_RB ,_, there_EX are_VBP other_JJ
        methods_NNS for_IN detection_NN of_IN point_NN mutations_NNS that_WDT can_MD be_VB
        compared_VBN to_TO ,_, or_CC used_VBD in_IN addition_NN to_TO ,_, the_DT method_NN presented_VBN
        here_RB ,_, including_VBG PTT_NNP [_NN 15_CD ]_NN ,_, DGGE_NNP [_NN 18_CD ]_NN ,_, and_CC DOVAM-S_NNP [_NN 19_CD
        ]_NN ._. More_JJR information_NN on_IN DGGE_NNP analysis_NN of_IN the_DT DMD_NNP can_MD be_VB
        found_VBN in_IN the_DT Leiden_NNP Muscular_NNP Dystrophy_NNP web_NN site_NN
        http_NN :_: /_NN /_NN www_NN ._. dmd_NN ._. nl_NN /_NN ._.
        Clinical_NNP laboratories_NNS planning_NN to_TO begin_VB testing_NN for_IN
        point_NN as_RB well_RB as_IN large_JJ mutations_NNS must_MD clearly_RB evaluate_VB
        possible_JJ technologies_NNS in_IN at_IN least_JJS three_CD areas_NNS :_:
        effectiveness_NN ,_, convenience_NN and_CC cost_NN ._.
        DHPLC_NNP followed_VBN by_IN sequencing_VBG improves_VBZ the_DT effectiveness_NN
        of_IN mutation_NN detection_NN from_IN 65_CD %_NN ,_, using_VBG the_DT existing_VBG
        multiplexed_JJ PCR_NNP technology_NN that_WDT detects_NNS large_JJ mutations_NNS
        only_RB ,_, to_TO approximately_RB 92_CD %_NN by_IN including_VBG detection_NN of_IN
        approximately_RB 75_CD %_NN of_IN point_NN mutations_NNS as_RB well_RB ._. Clinical_NNP
        laboratories_NNS that_WDT are_VBP planning_VBG to_TO screen_VB cohorts_NNS of_IN
        patients_NNS using_VBG the_DT technique_NN presented_VBN here_RB will_MD produce_VB
        three_CD important_JJ outcomes_NNS ._. The_DT first_JJ will_MD be_VB a_DT more_RBR accurate_JJ
        measure_NN of_IN the_DT effectiveness_NN of_IN DHPLC_NNP screening_NN for_IN
        sequence_NN variation_NN followed_VBN by_IN direct_JJ sequencing_VBG ._. The_DT
        second_NN will_MD be_VB improvements_NNS in_IN the_DT conditions_NNS for_IN mutation_NN
        detection_NN using_VBG DHPLC_NNP ._. As_IN new_JJ mutations_NNS are_VBP discovered_VBN ,_,
        they_PRP could_MD be_VB entered_VBN into_IN the_DT database_NN along_IN with_IN any_DT
        suggested_VBN improvements_NNS to_TO the_DT DHPLC_NNP conditions_NNS for_IN a_DT given_VBN
        fragment_NN /_NN alteration_NN ._. The_DT third_JJ will_MD be_VB a_DT collection_NN of_IN DNA_NNP ,_,
        RNA_NNP and_CC tissue_NN from_IN patients_NNS for_IN whom_WP all_DT 86_CD fragments_NNS were_VBD
        sequenced_JJ with_IN no_DT likely_JJ disease_NN causing_VBG mutations_NNS
        detected_VBD ._. This_DT will_MD prove_VB extremely_RB useful_JJ for_IN further_JJ
        investigations_NNS into_IN the_DT more_RBR subtle_JJ causes_NNS of_IN
        dystrophin-deficient_JJ muscular_JJ dystrophy_NN ._. Ultimately_RB ,_, this_DT
        will_MD provide_VB procedures_NNS for_IN the_DT detection_NN of_IN mutations_NNS in_IN
        dystrophin-absent_JJ patients_NNS that_WDT will_MD be_VB more_RBR
        comprehensive_JJ ._.
        The_DT convenience_NN of_IN DHPLC_NNP followed_VBN by_IN sequencing_VBG is_VBZ
        readily_RB apparent_JJ ._. It_PRP requires_VBZ neither_DT radioisotopes_NNS nor_CC
        ethidium_NN bromide_NN gels_NNS when_WRB combined_VBN with_IN a_DT core_NN sequencing_VBG
        facility_NN or_CC capillary_JJ sequencer_NN (_( See_VB Additional_JJ file_NN Bfor_NNP
        details_NNS )_) ._.
        We_PRP found_VBD that_IN the_DT cost_NN of_IN reagents_NNS for_IN DHPLC_NNP screening_NN
        followed_VBN by_IN direct_JJ sequencing_VBG was_VBD only_RB moderately_RB higher_JJR
        than_IN the_DT cost_NN for_IN the_DT existing_VBG multiplexed_JJ PCR_NNP test_NN ._. The_DT
        reagent_NN cost_NN of_IN the_DT existing_VBG multiplexed_JJ PCR_NNP diagnostic_JJ is_VBZ
        estimated_VBN at_IN $_$ 25_CD ._. 00_CD per_IN patient_NN ._. Increasing_VBG the_DT percentage_NN
        of_IN mutations_NNS detected_VBD in_IN patients_NNS from_IN the_DT current_JJ 65_CD %_NN to_TO
        approximately_RB 92_CD %_NN by_IN including_VBG point_NN mutations_NNS would_MD come_VB
        at_IN the_DT moderate_JJ increase_NN in_IN reagent_NN costs_NNS of_IN approximately_RB
        $_$ 57_CD ._. 75_CD per_IN patient_NN plus_CC a_DT moderate_JJ increase_NN in_IN other_JJ costs_NNS
        such_JJ as_IN consumables_NNS and_CC technician_NN time_NN ._. Although_IN the_DT
        initial_JJ investment_NN in_IN a_DT DHPLC_NNP system_NN is_VBZ not_RB minimal_JJ at_IN
        approximately_RB $_$ 80_CD ,_, 000_CD ,_, the_DT cost_NN can_MD be_VB amortized_JJ over_IN many_JJ
        patients_NNS and_CC the_DT DHPLC_NNP system_NN can_MD be_VB used_VBN in_IN the_DT molecular_JJ
        diagnosis_NN of_IN many_JJ other_JJ diseases_NNS in_IN addition_NN to_TO DMD_NNP ._. The_DT
        same_JJ ,_, of_IN course_NN ,_, is_VBZ true_JJ for_IN the_DT purchase_NN of_IN an_DT automated_VBN
        sequencer_NN ._. Details_NNS of_IN the_DT reagent_NN costs_NNS per_IN patient_NN
        calculations_NNS are_VBP attached_VBN as_IN Additional_JJ file_NN A_DT ._. Briefly_NNP ,_, we_PRP
        assumed_VBD that_IN likely_JJ disease-causative_JJ mutations_NNS would_MD be_VB
        found_VBN ,_, on_IN average_JJ ,_, within_IN approximately_RB 43_CD fragments_NNS ._. We_PRP
        calculated_VBD the_DT cost_NN of_IN reagents_NNS per_IN 50_CD μl_NN PCR_NNP and_CC the_DT cost_NN
        of_IN reagents_NNS to_TO run_VB a_DT sample_NN on_IN the_DT DHPLC_NNP system_NN and_CC
        multiplied_VBN by_IN the_DT number_NN of_IN samples_NNS required_VBN to_TO screen_VB a_DT
        patient_NN ._. We_PRP estimated_VBD that_IN there_EX will_MD be_VB four_CD fragments_NNS per_IN
        patient_NN that_WDT require_VBP sequencing_VBG ._. We_PRP calculated_VBD the_DT reagent_NN
        costs_NNS to_TO amplify_VB ,_, purify_NN and_CC sequence_NN these_DT four_CD strands_NNS
        per_IN patient_NN in_IN both_DT directions_NNS ._. We_PRP then_RB combined_VBD the_DT cost_NN
        of_IN the_DT existing_VBG multiplex_NN test_NN for_IN 100_CD %_NN of_IN patients_NNS with_IN
        the_DT cost_NN of_IN DHPLC_NNP screening_NN followed_VBN by_IN direct_JJ sequencing_VBG
        for_IN 35_CD %_NN of_IN patients_NNS to_TO arrive_VB at_IN an_DT average_JJ cost_NN per_IN
        patient_NN and_CC the_DT increase_NN over_IN the_DT average_JJ cost_NN per_IN patient_NN
        for_IN the_DT existing_VBG multiplexed_JJ PCR_NNP test_NN alone_RB ._.
      
      
        Conclusion_NNP
        Point_NNP mutations_NNS can_MD be_VB found_VBN in_IN both_DT DMD_NNP /_NN BMD_NNP male_JJ
        patients_NNS and_CC asymptomatic_JJ or_CC manifesting_VBG DMD_NNP /_NN BMD_NNP carrier_NN
        females_NNS via_IN an_DT effective_JJ and_CC convenient_JJ process_NN using_VBG
        automated_VBN DHPLC_NNP screening_NN for_IN variation_NN and_CC direct_JJ
        sequencing_VBG for_IN confirmation_NN and_CC analysis_NN at_IN a_DT moderate_JJ
        increase_NN in_IN cost_NN per_IN patient_NN ._. We_PRP have_VBP shown_VBN that_IN it_PRP is_VBZ now_RB
        feasible_JJ for_IN clinical_JJ laboratories_NNS to_TO begin_VB testing_NN for_IN
        both_DT point_NN mutations_NNS and_CC large_JJ mutations_NNS in_IN the_DT dystrophin_NN
        gene_NN using_VBG this_DT or_CC one_CD of_IN the_DT other_JJ available_JJ methods_NNS for_IN
        mutation_NN detection_NN ._. The_DT detection_NN rate_NN for_IN all_DT mutations_NNS in_IN
        the_DT DMD_NNP gene_NN can_MD be_VB increased_VBN from_IN the_DT present_JJ 65_CD %_NN to_TO above_IN
        92_CD %_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Patient_NNP materials_NNS
          After_IN reviewing_VBG medical_JJ records_NNS ,_, we_PRP studied_VBD eight_CD male_JJ
          patients_NNS who_WP had_VBD been_VBN diagnosed_VBN as_IN having_VBG DMD_NNP based_VBN on_IN
          pathology_NN lab_NN report_NN ,_, disease_NN progression_NN and_CC
          abnormalities_NNS in_IN the_DT level_NN of_IN dystrophin_NN expression_NN
          either_CC by_IN immunofluorescence_NN or_CC western_JJ blot_NN analysis_NN ._. In_IN
          each_DT patient_NN ,_, no_DT large_JJ deletion_NN or_CC duplication_NN was_VBD
          detected_VBN using_VBG the_DT currently_RB used_VBN primers_NNS ._. This_DT current_JJ
          set_VBN consists_VBZ of_IN primers_NNS to_TO amplify_VB the_DT dp_NN 427_CD m_NN promoter_NN
          including_VBG exon_NN 1_CD and_CC exons_NNS 3_CD ,_, 4_CD ,_, 6_CD ,_, 8_CD ,_, 12_CD ,_, 13_CD ,_, 17_CD ,_, 19_CD ,_,
          43_CD ,_, 44_CD ,_, 45_CD ,_, 47_CD ,_, 48_CD ,_, 49_CD ,_, 50_CD ,_, 51_CD ,_, 52_CD ,_, 60_CD ._. Although_IN none_NN of_IN
          the_DT patients_NNS had_VBD a_DT family_NN history_NN of_IN DMD_NNP ,_, all_DT were_VBD
          determined_VBN to_TO be_VB highly_RB likely_JJ to_TO have_VB dystrophin_NN gene_NN
          mutations_NNS ,_, as_IN opposed_VBN to_TO other_JJ genetic_JJ causes_NNS of_IN muscular_JJ
          dystrophy_NN (_( see_VB Table_NNP 1_LS )_) ._.
          Genomic_NNP DNA_NNP was_VBD prepared_VBN from_IN whole_JJ blood_NN using_VBG the_DT
          Puregene_NNP kit_NN (_( Gentra_NNP Systems_NNPS ,_, Minneapolis_NNP ,_, Mn_NNP ._. )_) ._. DNA_NNP
          concentration_NN was_VBD determined_VBN by_IN spectrophotometry_NN ._. This_DT
          study_NN was_VBD approved_VBN by_IN the_DT Children_NNP 's_POS Hospital_NNP
          institutional_JJ review_NN board_NN ,_, and_CC informed_VBD consent_NN was_VBD
          obtained_VBN from_IN all_DT adult_NN participating_VBG subjects_NNS and_CC from_IN
          parents_NNS or_CC legal_JJ guardians_NNS of_IN participating_VBG minors_NNS ._.
        
        
          Primer_NNP /_NN fragment_NN design_NN
          Exonic_NNP and_CC intronic_JJ sequence_NN for_IN dp_NN 427_CD m_NN was_VBD obtained_VBN
          from_IN NCBI_NNP /_NN Genbank_NNP using_VBG an_DT iterative_JJ electronic_JJ data_NNS
          mining_NN approach_NN via_IN the_DT National_NNP Center_NNP for_IN Biotechnology_NNP
          Information_NNP web_NN site_NN pages_NNS for_IN Blast_NNP searches_NNS and_CC Entrez_NNP
          queries_NNS www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN blast_NN /_NN Blast_NNP ._. cgiand_NN
          http_NN :_: /_NN /_NN www_NN ._. ncbi_NN ._. nlm_NN ._. nih_NN ._. gov_NN /_NN entrez_NN /_NN query_NN ._. fcgi_NN ?_. db_NN =_SYM Nucleotide_NNP ._.
          Starting_VBG with_IN known_VBN mRNA_NN sequence_NN (_( accession_NN #_# Ml_NNP 8533_CD )_) ,_,
          the_DT accession_NN numbers_NNS referenced_JJ (_( Table_NNP 3_LS )_) contain_VB most_JJS
          of_IN the_DT sequence_NN obtained_VBN ._. Many_JJ compromises_NNS are_VBP involved_VBN
          in_IN selection_NN of_IN primer_NN sequences_NNS ._. The_DT primers_NNS listed_VBN in_IN
          Additional_JJ file_NN A_DT :_: Primer_NNP sequences_NNS and_CC DHPLC_NNP
          temperatures_NNS Excel_NNP spreadsheet_NN were_VBD designed_VBN using_VBG the_DT
          Primer_NNP 3_CD (_( Whitehead_NNP Institute_NNP ,_, Cambridge_NNP ,_, Ma_NNP ._. )_) and_CC OLIGO_NNP
          6_CD ._. 0_CD (_( Molecular_NNP Biology_NNP Insights_NNPS ,_, Inc_NNP ._. ,_, Cascade_NNP ,_, Co_NNP ._. )_)
          software_NN packages_NNS with_IN four_CD goals_NNS in_IN mind_NN ._. These_DT
          were_VBD :_:
          a_DT )_) to_TO include_VB 30_CD -_: 100_CD bases_NNS of_IN intronic_JJ sequence_NN
          adjacent_JJ to_TO each_DT exon_NN at_IN both_DT the_DT 5_CD '_POS and_CC 3_CD '_POS ends_NNS of_IN the_DT
          exon_NN
          b_SYM )_) to_TO create_VB a_DT single_JJ ,_, visible_JJ ,_, specific_JJ band_NN of_IN
          reasonable_JJ intensity_NN when_WRB analyzed_VBD on_IN agarose_NN gel_NN
          c_SYM )_) to_TO create_VB fragments_NNS that_WDT have_VBP melting_VBG
          characteristics_NNS appropriate_JJ for_IN cost-effective_JJ DNA_NNP
          variation_NN screening_NN by_IN DHPLC_NNP analysis_NN ._. Appropriate_NNP
          melting_VBG characteristics_NNS are_VBP such_JJ that_IN variations_NNS from_IN
          unaffected_JJ sequence_NN in_IN any_DT portion_NN of_IN the_DT fragment_NN will_MD
          be_VB detected_VBN using_VBG ideally_RB only_RB one_CD running_VBG temperature_NN
          but_CC no_RB more_JJR than_IN three_CD (_( see_VB Additional_JJ file_NN A_DT :_: Primer_NNP
          sequences_NNS and_CC DHPLC_NNP temperatures_NNS Excel_NNP spreadsheet_NN )_)
          d_SYM )_) to_TO provide_VB clean_VB sequence_NN in_IN both_DT directions_NNS
          without_IN resorting_VBG to_TO additional_JJ primers_NNS designed_VBN simply_RB
          for_IN sequencing_VBG the_DT amplicon_NN ._.
          All_DT these_DT goals_NNS were_VBD met_VBN by_IN the_DT primer_NN set_VBN presented_VBN
          here_RB ._. The_DT primer_NN set_VBN and_CC the_DT sequence_NN of_IN the_DT fragments_NNS as_RB
          well_RB as_IN additional_JJ intron_NN sequence_NN are_VBP available_JJ on_IN the_DT
          Leiden_NNP Muscular_NNP Dystrophy_NNP pages_NNS
          http_NN :_: /_NN /_NN www_NN ._. dmd_NN ._. nl_NN /_NN DMD_NNP __NN DHPLC_NNP ._. html_NN ._. Obviously_RB ,_, many_JJ of_IN
          these_DT primers_NNS could_MD be_VB grouped_VBN into_IN sets_NNS for_IN multiplex_NN
          PCR_NNP in_IN order_NN to_TO initially_RB screen_VB for_IN large_JJ mutations_NNS
          using_VBG the_DT same_JJ primers_NNS presented_VBN here_RB ._. Multiplexed_NNP PCR_NNP
          could_MD be_VB run_VBN on_IN the_DT DHPLC_NNP system_NN in_IN a_DT size_NN detection_NN mode_NN
          for_IN detection_NN of_IN large_JJ deletion_NN /_NN duplication_NN alterations_NNS
          in_IN males_NNS ._. A_DT page_NN or_CC process_NN could_MD be_VB provided_VBN within_IN the_DT
          Leiden_NNP Muscular_NNP Dystrophy_NNP pages_NNS for_IN posting_VBG of_IN suggested_VBD
          improvements_NNS to_TO DHPLC_NNP conditions_NNS for_IN detection_NN of_IN
          specific_JJ alterations_NNS and_CC for_IN suggested_JJ primer_NN design_NN
          improvements_NNS ._. Quantitative_NNP PCR_NNP ,_, FISH_NNP (_( Fluorescent_NNP In-_NNP Situ_NNP
          Hybridization_NNP )_) or_CC MAPH_NNP (_( see_VB
          http_NN :_: /_NN /_NN www_NN ._. dmd_NN ._. nl_NN /_NN DMD_NNP __NN MAPH_NNP ._. html_NN )_) analysis_NN is_VBZ still_RB
          required_VBN for_IN detection_NN of_IN female_JJ carriers_NNS of_IN large_JJ
          deletion_NN /_NN duplication_NN alterations_NNS ._. Quantitative_NNP PCR_NNP can_MD be_VB
          performed_VBN on_IN the_DT DHPLC_NNP system_NN ,_, the_DT ABI_NNP 7700_CD Sequence_NNP
          Detector_NNP ,_, the_DT Bio-_NNP Rad_NNP iCycler_NN or_CC by_IN standard_JJ
          densitometric_JJ procedures_NNS ._.
        
        
          Amplification_NNP of_IN genomic_JJ DNA_NNP
          DNA_NNP was_VBD amplified_VBN in_IN a_DT final_JJ reaction_NN volume_NN of_IN 50_CD μl_NN
          by_IN using_VBG 100_CD ng_NN genomic_JJ DNA_NNP ,_, 10_CD x_SYM buffer_NN (_( ABgene_NNP Thermo_NNP
          Start_NNP AB-_NNP 0908_CD /_NN b_SYM ,_, ABgene_NNP ,_, Epson_NNP ,_, Surrey_NNP ,_, KT_NNP 19_CD 9_CD AP_NNP ,_, U_NNP ._. K_NNP ._. )_) ,_,
          1_CD ._. 5_CD mM_NN MgCl_NNP 
          2_CD ,_, 200_CD μM_NN each_DT dNTPs_NNS ,_, 0_CD ._. 27_CD μM_NN (_( 100_CD ng_NN )_)
          primers_NNS and_CC 1_CD ._. 25_CD units_NNS Thermo_NNP Start_NNP polymerase_NN
          (_( Abgene_NNP )_) ._.
          PCR_NNP cycling_NN conditions_NNS consisted_VBD of_IN an_DT initial_JJ
          denaturation_NN step_NN at_IN 95_CD °_NN C_NNP for_IN 15_CD min_NN ._. followed_VBN by_IN 35_CD
          cycles_NNS of_IN 94_CD °_NN C_NNP for_IN 5_CD s_VBZ ,_, the_DT specified_VBN annealing_VBG
          temperature_NN (_( indicated_VBD in_IN Additional_JJ file_NN A_DT :_: Primer_NNP
          sequences_NNS and_CC DHPLC_NNP temperatures_NNS Excel_NNP spreadsheet_NN )_) for_IN
          15_CD s_VBZ ,_, 72_CD °_NN C_NNP for_IN 30_CD s_VBZ and_CC ending_VBG with_IN a_DT final_JJ elongation_NN
          step_NN at_IN 72_CD °_NN C_NNP for_IN 3_CD min_NN ._.
        
        
          WAVE_NNP ®_NN system_NN DHPLC_NNP analysis_NN
          The_DT DHPLC_NNP instrument_NN we_PRP used_VBD is_VBZ the_DT WAVE_NNP ®_NN system_NN
          (_( Transgenomic_NNP Inc_NNP ._. ,_, Omaha_NNP ,_, Ne_NNP ._. )_) ._. Unpurified_NNP PCR_NNP amplicons_NNS
          from_IN patients_NNS were_VBD mixed_JJ in_IN a_DT 1_CD :_: 1_CD ratio_NN with_IN an_DT aliquot_NN
          of_IN unpurified_JJ PCR_NNP amplicon_NN from_IN an_DT unaffected_JJ male_NN ._. The_DT
          unaffected_JJ male_JJ amplicon_NN and_CC the_DT mix_NN were_VBD heated_VBN to_TO 95_CD °_NN C_NNP
          for_IN 5_CD min_NN ._. and_CC cooled_VBN slowly_RB over_IN 45_CD min_NN ._. to_TO 25_CD °_NN C_NNP in_IN a_DT
          thermocycler_NN ._. The_DT unaffected_JJ and_CC mixed_JJ reactions_NNS were_VBD
          then_RB run_VB at_IN pre-determined_JJ temperatures_NNS (_( see_VB Additional_JJ
          file_NN A_DT :_: Primer_NNP sequences_NNS and_CC DHPLC_NNP temperatures_NNS Excel_NNP
          spreadsheet_NN )_) on_IN the_DT WAVE_NNP ®_NN system_NN and_CC the_DT resultant_JJ
          chromatograms_NNS compared_VBN for_IN variation_NN in_IN shape_NN or_CC
          retention_NN time_NN ._. Figure_NN 4_CD adepicts_NNS typical_JJ chromatograms_NNS
          for_IN samples_NNS in_IN which_WDT no_DT variation_NN from_IN unaffected_JJ control_NN
          is_VBZ detectable_JJ ._. Figure_NN 4_CD band_NN 4_CD cshow_NN the_DT mutation_NN and_CC size_NN
          standards_NNS ._. We_PRP recommend_VBP that_IN the_DT first_JJ five_CD injections_NNS of_IN
          each_DT run_NN should_MD be_VB a_DT blank_JJ (_( 0_CD volume_NN )_) ,_, the_DT size_NN standard_JJ ,_,
          a_DT blank_NN ,_, the_DT mutation_NN standard_JJ and_CC a_DT blank_NN ._. The_DT retention_NN
          time_NN and_CC peak_NN /_NN trough_NN height_NN of_IN the_DT standards_NNS should_MD be_VB
          compared_VBN to_TO those_DT obtained_VBD the_DT very_RB first_JJ time_NN the_DT
          standards_NNS were_VBD run_VBN (_( at_IN installation_NN of_IN the_DT system_NN )_) to_TO
          ascertain_VB the_DT separation_NN performance_NN of_IN the_DT column_NN ._. If_IN
          they_PRP vary_VBP by_IN more_JJR than_IN 10_CD %_NN ,_, the_DT run_NN should_MD be_VB aborted_JJ and_CC
          the_DT column_NN cleaned_VBN or_CC other_JJ preventative_JJ /_NN curative_JJ steps_NNS
          taken_VBN to_TO return_VB the_DT system_NN to_TO operation_NN within_IN the_DT
          specifications_NNS for_IN the_DT standards_NNS as_IN stated_VBN in_IN the_DT systems_NNS
          manual_JJ ._.
        
        
          Sequence_NNP analysis_NN
          PCR_NNP amplicons_NNS were_VBD purified_JJ using_VBG the_DT QIAquick_NNP PCR_NNP
          Purification_NNP Kit_NNP (_( Qiagen_NNP ,_, Valencia_NNP ,_, Ca_MD ._. )_) ._. DNA_NNP
          concentration_NN was_VBD determined_VBN by_IN spectrophotometry_NN ._. Cycle_NNP
          sequencing_VBG extension_NN products_NNS were_VBD created_VBN in_IN a_DT final_JJ
          volume_NN 20_CD μl_NN reaction_NN using_VBG 8_CD μl_NN H_NNP 
          2_CD O_NNP ,_, 4_CD ul_NN forward_RB or_CC reverse_VB primer_NN at_IN
          20_CD ng_NN /_NN μl_NN ,_, 4_CD μl_NN template_NN DNA_NNP (_( amplicon_NN )_) at_IN 4_CD ng_NN /_NN μl_NN for_IN
          fragments_NNS up_IN to_TO 200_CD bp_NN ,_, 5_CD ng_NN /_NN μl_NN for_IN fragments_NNS between_IN 200_CD
          and_CC 400_CD bp_NN and_CC 6_CD ng_NN /_NN μl_NN for_IN fragments_NNS greater_JJR than_IN 400_CD bp_NN ,_,
          2_CD μl_NN Big_NNP Dye_NNP Terminator_NNP Ready_NNP Reaction_NNP mix_NN (_( PE-ABI_NNP ,_,
          Foster_NNP City_NNP ,_, Ca_MD ._. )_) and_CC 2_CD μl_NN HalfBD_NNP (_( Genepak_NNP ,_, Inc_NNP ._. Stony_NNP
          Brook_NNP ,_, N_NNP ._. Y_NNP ._. )_) ._.
          Cycle_NNP sequencing_VBG conditions_NNS consisted_VBD of_IN an_DT initial_JJ
          denaturation_NN step_NN at_IN 95_CD °_NN C_NNP for_IN 4_CD min_NN ._. followed_VBN by_IN 25_CD
          cycles_NNS of_IN 95_CD °_NN C_NNP for_IN 12_CD s_VBZ ,_, 49_CD °_NN C_NNP for_IN 6_CD s_VBZ ,_, and_CC 60_CD °_NN C_NNP for_IN 4_CD
          min_NN ._. Unincorporated_NNP dye_NN and_CC other_JJ contaminants_NNS were_VBD
          removed_VBN with_IN SEQueaky_NNP Kleen_NNP 96_CD well_RB kit_NN (_( BIO-RAD_NNP
          Laboratories_NNPS ,_, Hercules_NNP ,_, Ca_MD ._. )_) Both_DT strands_NNS were_VBD sequenced_JJ
          on_IN an_DT ABI_NNP 373_CD automated_VBN sequencer_NN ._. Data_NNP was_VBD analyzed_VBN with_IN
          the_DT SequencherTM_NNP software_NN (_( Genecodes_NNP Inc_NNP ._. Ann_NNP Arbor_NNP ,_,
          Michigan_NNP )_) ._.
        
      
      
        Abbreviations_NNP
        DHPLC_NNP :_: Denaturing_NNP high_JJ performance_NN liquid_JJ
        chromatography_NN
        DMD_NNP :_: Duchenne_NNP Muscular_NNP Dystrophy_NNP
        BMD_NNP :_: Becker_NNP Muscular_NNP Dystrophy_NNP
        PCR_NNP :_: Polymerase_NNP chain_NN reaction_NN
        PTT_NNP :_: Protein_NNP Truncation_NNP Test_NNP
        DGGE_NNP :_: Denaturing_NNP Gradient_NNP Gel_NNP Electrophoresis_NNP
        DOVAM_NNP :_: Detection_NNP of_IN Virtually_RB All_DT Mutations_NNP
        Additional_JJ file_NN A_DT :_: Primer_NNP sequences_NNS and_CC DHPLC_NNP
        temperatures_NNS Excel_NNP spreadsheet_NN
        This_DT file_NN contains_VBZ a_DT database_NN that_WDT includes_VBZ primer_NN
        sequences_NNS for_IN amplifying_VBG each_DT of_IN the_DT dystrophin_NN screening_NN
        fragments_NNS ,_, fragment_NN length_NN ,_, and_CC the_DT suggested_VBD first_JJ pass_NN
        and_CC second_JJ pass_NN WAVE_NNP ®_NN oven_NN temperatures_NNS ._.
        Click_NNP here_RB for_IN file_NN
        Additional_JJ file_NN B_NNP :_: Details_NNS regarding_VBG procedure_NN and_CC cost_NN
        of_IN DHPLC_NNP screening_NN ,_, observations_NNS regarding_VBG the_DT dystrophin_NN
        gene_NN ,_, and_CC statistics_NNS about_IN DMD_NNP carrier_NN females_NNS ._.
        This_DT file_NN outlines_VBZ the_DT expenditures_NNS and_CC procedures_NNS
        related_VBN to_TO DHPLC_NNP screening_NN and_CC comments_NNS upon_IN interesting_JJ
        observations_NNS made_VBN as_IN a_DT result_NN of_IN this_DT project_NN ._.
        Click_NNP here_RB for_IN file_NN
      
    
  
